Antiviral Drugs


Antiviral drugs have now been developed against influenza, herpes, human immunodeficiency viruses, hepatitis C and hepatitis B. Drug resistance is a practical problem and is stimulating the wider search for new drugs using compound libraries, molecular technology and particularly X‐ray crystallography whilst drug combinations are used in acquired immune deficiency syndrome (AIDS) patients and hepatitis to reduce the opportunities for virus mutations. The threat of a global outbreak of chicken influenza (H5N1) has led to government stockpiling of the new antiflu drugs, the neuraminidase inhibitors. Pegylated and other interferons are used in drug combinations with hepatitis B and C patients.

Keywords: antivirals; influenza; HIV; herpes; hepatitis

Figure 1.

Ribbon drawing of influenza A neuraminidase (NA) enzyme. (a) Normal influenza NA and (b) oseltamivir inhibitor bound to the active site of the NA.

Figure 2.

Space‐filling model of influenza A NA enzyme with zanamivir inhibitor bound at the active site.



Bauer DJ, St Vincent L, Kempe CH and Downie AW (1963) Prophylactic treatment of smallpox contacts with N‐methyl‐isatin‐β‐thiosemicarbazone (compound 33T57, marboran). Lancet ii: 494–496.

Collier L and Oxford JS (2007) Human Virology: A Text for Students of Medicine and Dentistry, 3rd edn. Oxford: Oxford University Press.

De Clercq (2004) Antiviral drugs in current clinical use. Journal of Clinical Virology 30: 115–133.

Elion GB, Furman PA, Fyfe JA et al. (1977) Selectivity of action of an antiherpetic agent, 9‐(2‐hydroxyethoxymethyl) guanine. Proceedings of the National Academy of Sciences of the USA 74: 5716–5720.

Fauci AS (1999) The AIDS epidemic; considerations for the 21st century. New England Journal of Medicine 341: 1046–1050.

Field HJ and Wassilew S (eds) (1997) Managing herpesvirus infections in the 21st century. Proceedings of a meeting held in Limassol, Cyprus. Antiviral Chemistry and Chemotherapy 8 (suppl. 1).

Gubareva LV, Kaiser L and Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355: 827–835.

Laver WG, Bischofberger N and Webster RG (1999) Disarming flu viruses. Scientific American 280(1): 78–87.

Longini IM Jr, Nizam A, Xu S et al. (2005) Containing pandemic influenza at the source. Science 309: 1083–1087.

Pawlotsky JM, Chevaliez S and McHutchinson JG (2007) The hepatitis C virus recycle as a target for new antiviral therapies. Gastroenterology 132: 1979–1998.

Smith TJ, Kremer HJ, Luo M et al. (1986) The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233: 1286–1293.

Stuart‐Harris CH, Schild GC and Oxford JS (1985) Influenza: The Viruses and the Disease. London: Edward Arnold.

Webster RG, Peiris M, Chen H and Guan Y (2006) H5N1 outbreaks and enzootic influenza. Emerging Infectious Diseases 12: 3–8.

Further Reading

Cedric Mims (2000) The War Within Us, Everyones Guide to Infection and Immunity, p. 278. London: Academic Press.

Knipe DM and Howley PM (eds) (2001) Fields Virology, 4th edn, vols. 1 and 2. Philadelphia: Lippincott Williams and Wilkins.

Mahy BWJ and ter Meulen V (eds) (2005) Topley and Wilsons Microbiology and Microbial Infections. 10th edn, Virology, vols. 1 and 2. London: Hodder Arnold.

Mettenleiter TC and Sobrino F (eds) (2008) Animal Viruses. Molecular Biology, p. 531. UK: Caister Academic Press.

Torrence PF (ed.) (2005) Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats, p. 420. New Jersey: Wiley.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Oxford, John S(Sep 2008) Antiviral Drugs. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0000410.pub2]